PharmaEssentia seeks to expand access to blood cancer drug in Europe - Focus Taiwan

Taiwan-based drugmaker PharmaEssentia Corp. is seeking to expand patient access to its blood cancer drug Ropeg in Europe, where the treatment has yet to receive regulatory approval for essential thrombocythemia (ET), despite securing approval in several major markets.